Thank you, too, Bernard.
As you may know, I've followed this company since their IPO in 2000. I'm a little unsure of their commercialization strategy. It's a big winner if it works, but a risky approach; it seems simpler, cheaper, and easier to identify the proteins for your diagnostic test, and then market an ELISA. But no, they're going to do it with their system. As Rick might say, it won't be boring. I think a partnership deal with a major player (Correlogic managed to sign one with Lab Corp, but then couldn't validate their test) could yield something like a double very quickly.
Any partnership would help; the magnitude of the share price move will obviously depend on the terms of the deal. CIPH needs something either quick, or up front cash.
However, I have to contest your reports of insider buying. I see no such thing (there were some institutional moves in February that I have not checked), just some options issued. Check the Form 4s:
sec.gov
You got a source for your contention that "There has been reports of significant insiders pick up of stock in the last few months."?
Cheers, Tuck |
